Literature DB >> 31444154

ZBTB7A Mediates the Transcriptional Repression Activity of the Androgen Receptor in Prostate Cancer.

Dong Han1, Sujun Chen2,3, Wanting Han1, Shuai Gao1, Jude N Owiredu1, Muqing Li1, Steven P Balk4, Housheng Hansen He5,3, Changmeng Cai6.   

Abstract

Loss of expression of context-specific tumor suppressors is a critical event that facilitates the development of prostate cancer. Zinc finger and BTB domain containing transcriptional repressors, such as ZBTB7A and ZBTB16, have been recently identified as tumor suppressors that play important roles in preventing prostate cancer progression. In this study, we used combined ChIP-seq and RNA-seq analyses of prostate cancer cells to identify direct ZBTB7A-repressed genes, which are enriched for transcriptional targets of E2F, and identified that the androgen receptor (AR) played a critical role in the transcriptional suppression of these E2F targets. AR recruitment of the retinoblastoma protein (Rb) was required to strengthen the E2F-Rb transcriptional repression complex. In addition, ZBTB7A was rapidly recruited to the E2F-Rb binding sites by AR and negatively regulated the transcriptional activity of E2F1 on DNA replication genes. Finally, ZBTB7A suppressed the growth of castration-resistant prostate cancer (CRPC) in vitro and in vivo, and overexpression of ZBTB7A acted in synergy with high-dose testosterone treatment to effectively prevent the recurrence of CRPC. Overall, this study provides novel molecular insights of the role of ZBTB7A in CRPC cells and demonstrates globally its critical role in mediating the transcriptional repression activity of AR. SIGNIFICANCE: ZBTB7A is recruited to the E2F-Rb binding sites by AR and negatively regulates the transcriptional activity of E2F1 on DNA replication genes. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31444154      PMCID: PMC6801099          DOI: 10.1158/0008-5472.CAN-19-0815

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

1.  Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1.

Authors:  Changmeng Cai; Housheng Hansen He; Sen Chen; Ilsa Coleman; Hongyun Wang; Zi Fang; Shaoyong Chen; Peter S Nelson; X Shirley Liu; Myles Brown; Steven P Balk
Journal:  Cancer Cell       Date:  2011-10-18       Impact factor: 31.743

2.  Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein.

Authors:  Shuai Gao; Yanfei Gao; Housheng Hansen He; Dong Han; Wanting Han; Amy Avery; Jill A Macoska; Xiaming Liu; Sen Chen; Fen Ma; Shaoyong Chen; Steven P Balk; Changmeng Cai
Journal:  Cell Rep       Date:  2016-10-18       Impact factor: 9.423

3.  PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy.

Authors:  Chen-Lin Hsieh; Ginevra Botta; Shuai Gao; Tiantian Li; Eliezer M Van Allen; Daniel J Treacy; Changmeng Cai; Housheng Hansen He; Christopher J Sweeney; Myles Brown; Steven P Balk; Peter S Nelson; Levi A Garraway; Philip W Kantoff
Journal:  Cancer Res       Date:  2015-03-25       Impact factor: 12.701

4.  ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.

Authors:  Changmeng Cai; Hongyun Wang; Housheng Hansen He; Sen Chen; Lingfeng He; Fen Ma; Lorelei Mucci; Qianben Wang; Christopher Fiore; Adam G Sowalsky; Massimo Loda; X Shirley Liu; Myles Brown; Steven P Balk; Xin Yuan
Journal:  J Clin Invest       Date:  2013-02-15       Impact factor: 14.808

5.  Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer.

Authors:  Changmeng Cai; Hongyun Wang; Youyuan Xu; Shaoyong Chen; Steven P Balk
Journal:  Cancer Res       Date:  2009-07-07       Impact factor: 12.701

6.  Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.

Authors:  Benjamin A Teply; Hao Wang; Brandon Luber; Rana Sullivan; Irina Rifkind; Ashley Bruns; Avery Spitz; Morgan DeCarli; Victoria Sinibaldi; Caroline F Pratz; Changxue Lu; John L Silberstein; Jun Luo; Michael T Schweizer; Charles G Drake; Michael A Carducci; Channing J Paller; Emmanuel S Antonarakis; Mario A Eisenberger; Samuel R Denmeade
Journal:  Lancet Oncol       Date:  2017-12-14       Impact factor: 41.316

7.  Physiological normal levels of androgen inhibit proliferation of prostate cancer cells in vitro.

Authors:  Weitao Song; Mohit Khera
Journal:  Asian J Androl       Date:  2014 Nov-Dec       Impact factor: 3.285

8.  The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc.

Authors:  John R Prensner; Wei Chen; Sumin Han; Matthew K Iyer; Qi Cao; Vishal Kothari; Joseph R Evans; Karen E Knudsen; Michelle T Paulsen; Mats Ljungman; Theodore S Lawrence; Arul M Chinnaiyan; Felix Y Feng
Journal:  Neoplasia       Date:  2014-11-20       Impact factor: 5.715

9.  Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression.

Authors:  Yajia Zhang; Sethuramasundaram Pitchiaya; Marcin Cieślik; Yashar S Niknafs; Jean C-Y Tien; Yasuyuki Hosono; Matthew K Iyer; Sahr Yazdani; Shruthi Subramaniam; Sudhanshu K Shukla; Xia Jiang; Lisha Wang; Tzu-Ying Liu; Michael Uhl; Alexander R Gawronski; Yuanyuan Qiao; Lanbo Xiao; Saravana M Dhanasekaran; Kristin M Juckette; Lakshmi P Kunju; Xuhong Cao; Utsav Patel; Mona Batish; Girish C Shukla; Michelle T Paulsen; Mats Ljungman; Hui Jiang; Rohit Mehra; Rolf Backofen; Cenk S Sahinalp; Susan M Freier; Andrew T Watt; Shuling Guo; John T Wei; Felix Y Feng; Rohit Malik; Arul M Chinnaiyan
Journal:  Nat Genet       Date:  2018-05-28       Impact factor: 38.330

10.  Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer.

Authors:  Francesco Crea; Akira Watahiki; Luca Quagliata; Hui Xue; Larissa Pikor; Abhijit Parolia; Yuwei Wang; Dong Lin; Wan L Lam; William L Farrar; Takao Isogai; Rudolf Morant; Serenella Castori-Eppenberger; Kim N Chi; Yuzhuo Wang; Cheryl D Helgason
Journal:  Oncotarget       Date:  2014-02-15
View more
  8 in total

1.  Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer.

Authors:  Wanting Han; Mingyu Liu; Dong Han; Anthia A Toure; Muqing Li; Anna Besschetnova; Zifeng Wang; Susan Patalano; Jill A Macoska; Hung-Ming Lam; Eva Corey; Housheng Hansen He; Shuai Gao; Steven P Balk; Changmeng Cai
Journal:  Mol Ther       Date:  2022-02-02       Impact factor: 12.910

Review 2.  Role of ZBTB7A zinc finger in tumorigenesis and metastasis.

Authors:  Atul Kumar Singh; Shiv Verma; Prem Prakash Kushwaha; Kumari Sunita Prajapati; Mohd Shuaib; Shashank Kumar; Sanjay Gupta
Journal:  Mol Biol Rep       Date:  2021-05-20       Impact factor: 2.316

3.  ZBTB7A functioned as an oncogene in colorectal cancer.

Authors:  Li Wang; Meng-Xia Zhang; Mei-Fang Zhang; Zi-Wei Tu
Journal:  BMC Gastroenterol       Date:  2020-11-09       Impact factor: 3.067

4.  Identification of RNA-binding protein SNRPA1 for prognosis in prostate cancer.

Authors:  Penghui Yuan; Le Ling; Xintao Gao; Taotao Sun; Jianping Miao; Xianglin Yuan; Jihong Liu; Zhihua Wang; Bo Liu
Journal:  Aging (Albany NY)       Date:  2021-01-15       Impact factor: 5.682

5.  The Prognostic Value of the DNA Repair Gene Signature in Head and Neck Squamous Cell Carcinoma.

Authors:  Ruijie Ming; Enhao Wang; Jiahui Wei; Jinxiong Shen; Shimin Zong; Hongjun Xiao
Journal:  Front Oncol       Date:  2021-07-30       Impact factor: 6.244

6.  Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by PKCβ1.

Authors:  James E Melnyk; Veronica Steri; Hao G Nguyen; Y Christina Hwang; John D Gordan; Byron Hann; Felix Y Feng; Kevan M Shokat
Journal:  Oncogene       Date:  2022-01-27       Impact factor: 8.756

7.  ZBTB7A, a miR-144-3p targeted gene, accelerates bladder cancer progression via downregulating HIC1 expression.

Authors:  Junqiang Liu; Zhiyuan Chou; Chun Li; Kai Huang; Xuejian Wang; Xiunan Li; Chuanchun Han; Abdullah Al-Danakh; Xiaodong Li; Xishuang Song
Journal:  Cancer Cell Int       Date:  2022-05-02       Impact factor: 6.429

8.  ZBTB7A promotes virus-host homeostasis during human coronavirus 229E infection.

Authors:  Xinyu Zhu; Joseph D Trimarco; Courtney A Williams; Alejandro Barrera; Timothy E Reddy; Nicholas S Heaton
Journal:  Cell Rep       Date:  2022-10-05       Impact factor: 9.995

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.